|
【结 构 式】 
|
【分子编号】62065 【品名】tert-butyl (1R,4S,11Z)-11-[(tert-butoxycarbonyl)amino]-1-(4-chlorobenzyl)-15,15-dimethyl-4-(1-naphthylmethyl)-2,5,13-trioxo-14-oxa-3,6,10,12-tetraaza-11-hexadecen-1-ylcarbamate 【CA登记号】 |
【 分 子 式 】C41H55ClN6O8 【 分 子 量 】795.37604 【元素组成】C 61.91% H 6.97% Cl 4.46% N 10.57% O 16.09% |
与该中间体有关的原料药合成路线共 1 条
合成路线1
该中间体在本合成路线中的序号：(X)Coupling between N-Boc-D-(4-chlorophenyl)alanine succinimidyl ester (VI) and L-naphthylalanine methyl ester (VII) affords the protected dipeptide (VIII). The methyl ester group of (VIII) is hydrolyzed by means of LiOH to produce the carboxylic acid (IX), which is subsequently coupled to the di-Boc-protected noragmatine (V), yielding amide (X). Finally, acidic cleavage of the Boc protecting groups of (X) leads to the title compound
| 【1】 Szelke, M.; Evans, D.M.; Jones, D.M. (Ferring AB); Kininogen inhibitors. WO 9507291 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (V) | 26836 | tert-butyl (Z)-[(3-aminopropyl)amino][(tert-butoxycarbonyl)amino]methylidenecarbamate | C14H28N4O4 | 详情 | 详情 | |
| (VI) | 62061 | tert-butyl (1R)-1-(4-chlorobenzyl)-2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-2-oxoethylcarbamate | C18H21ClN2O6 | 详情 | 详情 | |
| (VII) | 62062 | methyl (2S)-2-amino-3-(1-naphthyl)propanoate | C14H15NO2 | 详情 | 详情 | |
| (VIII) | 62063 | methyl (2S)-2-{[(2R)-2-[(tert-butoxycarbonyl)amino]-3-(4-chlorophenyl)propanoyl]amino}-3-(1-naphthyl)propanoate | C28H31ClN2O5 | 详情 | 详情 | |
| (IX) | 62064 | (2S)-2-{[(2R)-2-[(tert-butoxycarbonyl)amino]-3-(4-chlorophenyl)propanoyl]amino}-3-(1-naphthyl)propanoic acid | C27H29ClN2O5 | 详情 | 详情 | |
| (X) | 62065 | tert-butyl (1R,4S,11Z)-11-[(tert-butoxycarbonyl)amino]-1-(4-chlorobenzyl)-15,15-dimethyl-4-(1-naphthylmethyl)-2,5,13-trioxo-14-oxa-3,6,10,12-tetraaza-11-hexadecen-1-ylcarbamate | C41H55ClN6O8 | 详情 | 详情 |
Extended Information